PDF4PRO ⚡AMP

Modern search engine that looking for books and documents around the web

Example: quiz answers

CSRC Presentation.Napa.2015

6/1/15 1 1 June 2, 2015 NASDAQ: DSCO surfactant : Where We Have and Where We Are Going 2 DISCLOSURE : Christina Joseph, BS, RRT-NPS Clinical R&D Specialist Discovery Labs Discovery Labs is a manufacturer of KL4 and holds patents for Aerosurf technology r 3 Opinions expressed in these slides represent the speaker s own opinions, and not those of speaker s employer or any other organization 6/1/15 2 4 Pulmonary Surfactants and Respiratory Distress Syndrome (RDS) 5 1. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J. 1999;13(6):1455 1476. 2. American Lung Association. State of Lung Disease in Diverse Communities (2010). Available at Accessed August 29, 2012 Neonatal Respiratory Distress Syndrome (RDS) Epidemiology Life-threatening in premature infants, whose lungs have not fully developed surfactant prevents alveolar collapse at low lung volume, and preserves bronchiolar patency during normal and forced respiration1 Most cases occur in babies born before 28 weeks Rare in infants born at full-term 16,268 infants suffered from RDS in 20052 An incidence rate of per 1000 In 2007, 735 deaths, or 17 per 100,000

Less Invasive Surfactant Administration: LISA • This method involves brief tracheal catheterization and has been extensively studied, with surfactant administered by using both a flexible feeding tube and a semi-rigid vascular catheter during nCPAP

Loading..

Tags:

  Administration, 2015, Presentation, Invasive, Less, Less invasive surfactant administration, Surfactant, Apna

Information

Domain:

Source:

Link to this page:

Please notify us if you found a problem with this document:

Spam in document Broken preview Other abuse

Transcription of CSRC Presentation.Napa.2015

Related search queries